NCT07178847

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 59 (estimated)
• Sponsor: Centre Jean Perrin · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment

Conditions

• Locally Advanced Head and Neck Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	blood sampling	The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy

Timeline

• Start date: 2025-10-13
• Primary completion: 2029-04-01
• Completion: 2031-07-01
• First posted: 2025-09-17
• Last updated: 2025-12-01

Locations

3 sites across 1 country: France